Clinical trial
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in…
NCT00034359 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00034359 |
|---|---|
| Title | Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection |
| Official title | A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Collaborators | Achillion, a wholly owned subsidiary of Alexion Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B, Chronic |
| Intervention type | Drug |
| Interventions | ACH-126, 443, Lamivudine, Placebo |
| Enrollment | 79 |
| Start date | Feb 1, 2002 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | Apr 29, 2002 |
| Last update posted | Feb 18, 2021 |
| Countries | Bulgaria, Federal Republic of Yugoslavia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: